Cargando…

Asymptomatic infection after BNT162b2 mRNA COVID-19 vaccination in multiple sclerosis patient

Detalles Bibliográficos
Autores principales:	Jakimovski, Dejan, Weinstock-Guttman, Bianca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8444159/ https://www.ncbi.nlm.nih.gov/pubmed/34529258 http://dx.doi.org/10.1007/s13760-021-01799-8

Ejemplares similares

Unusual lymphadenopathies secondary to the BNT162b2 mRNA Covid-19 vaccine
por: Felices-Farias, Jose Manuel, et al.
Publicado: (2022)

Unusual lymphadenopathies secondary to the BNT162b2 mRNA Covid-19 vaccine
por: Felices-Farias, Jose Manuel, et al.
Publicado: (2022)

Erythema nodosum triggered by BNT162b2 mRNA COVID-19 vaccine
por: Juddoo, Vanessa, et al.
Publicado: (2022)

Infections, Vaccines and Autoimmunity: A Multiple Sclerosis Perspective
por: Jakimovski, Dejan, et al.
Publicado: (2020)

Bilateral anterior uveitis after BNT162b2 mRNA vaccine: Case report
por: Duran, M.
Publicado: (2022)

Experience with SARS-CoV-2 BNT162b2 mRNA vaccine in dialysis patients
por: Yanay, Noa Berar, et al.
Publicado: (2021)

COVID-19 BNT162b2 mRNA vaccine for patients with type 2 diabetes mellitus
por: Paschou, Stavroula A., et al.
Publicado: (2022)

Relapse of neuromyelitis optica spectrum disorder after BNT162b2 mRNA Covid-19 vaccination
por: Wang, Qi, et al.
Publicado: (2023)

Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine
por: Ruhe, Johannes, et al.
Publicado: (2021)

Humoral response after 3 doses of the BNT162b2 mRNA COVID-19 vaccine in patients on hemodialysis
por: Ducloux, Didier, et al.
Publicado: (2021)

Patients with type 2 diabetes mellitus and response to COVID-19 BNT162b2 mRNA vaccine: correspondence
por: Sookaromdee, Pathum, et al.
Publicado: (2022)

Comparison of BNT162b2 (Pfizer–BioNtech) and mRNA-1273 (Moderna) SARS-CoV-2 mRNA vaccine immunogenicity in dialysis patients
por: Kaiser, Robert A., et al.
Publicado: (2021)

Successful alternative vaccination with BNT162b2 mRNA COVID-19 vaccine for new-onset IgA vasculitis after receiving mRNA-1273—case report
por: Morioka, Fumiyuki, et al.
Publicado: (2022)

Safety and BNT162b2 mRNA COVID-19 vaccination
por: Joob, Beuy, et al.
Publicado: (2021)

The role of Epstein-Barr virus in multiple sclerosis: from molecular pathophysiology to in vivo imaging
por: Guan, Yi, et al.
Publicado: (2019)

Factors associated with humoral response after BNT162b2 mRNA COVID-19 vaccination in kidney transplant patients
por: Ducloux, Didier, et al.
Publicado: (2021)

A novel adverse effect of the BNT162b2 mRNA vaccine: First episode of acute mania with psychotic features
por: Yesilkaya, Umit Haluk, et al.
Publicado: (2021)

Distinct glomerular disease association after vaccination with BNT162b2 and mRNA-1273: a VigiBase analysis
por: Kronbichler, Andreas, et al.
Publicado: (2022)

High response rate to BNT162b2 mRNA COVID-19 vaccine among self-care dialysis patients
por: Georgery, Hélène, et al.
Publicado: (2021)

Humoral response after BNT162b2 mRNA COVID-19 vaccination in patients on haemodialysis depends on immune status
por: Ducloux, Didier, et al.
Publicado: (2021)

Induction of immune response after SARS-CoV-2 mRNA BNT162b2 vaccination in healthcare workers
por: Zaffina, Salvatore, et al.
Publicado: (2021)

Coincidence of BNT162b2 mRNA COVID-19 vaccination and hashimoto thyroiditis presenting as atrioventricular block: Causality or casualty
por: Chien, Kuang-Jen, et al.
Publicado: (2023)

Multiple Sclerosis in Children: Differential Diagnosis, Prognosis, and Disease-Modifying Treatment
por: Jakimovski, Dejan, et al.
Publicado: (2021)

Comparison of mRNA Vaccinations with BNT162b2 or mRNA-1273 in Anti-CD20-Treated Multiple Sclerosis Patients
por: Hammer, Helly, et al.
Publicado: (2022)

Exacerbation of subacute cutaneous lupus erythematosus following vaccination with BNT162b2 mRNA vaccine
por: Niebel, Dennis, et al.
Publicado: (2021)

Pericarditis after administration of the BNT162b2 mRNA COVID-19 vaccine
por: Ramírez-García, Almudena, et al.
Publicado: (2021)

Correspondence Regarding “Tolerability of Coronavirus Disease 2019 Vaccines BNT162b2 and mRNA-1273 in Patients With Thymic Epithelial Tumors”
por: Takada, Kazuki, et al.
Publicado: (2021)

Three-month analysis of total humoral response to Pfizer BNT162b2 mRNA COVID-19 vaccination in healthcare workers
por: Salvagno, Gian Luca, et al.
Publicado: (2021)

Ruxolitinib does not impair humoral immune response to COVID-19 vaccination with BNT162b2 mRNA COVID-19 vaccine in patients with myelofibrosis
por: Caocci, Giovanni, et al.
Publicado: (2021)

Vaccine-induced immune thrombotic thrombocytopenia after the BNT162b2 mRNA Covid-19 vaccine: A case study
por: Rodríguez, Carmen, et al.
Publicado: (2021)

Neuroimaging Correlates of Patient-Reported Outcomes in Multiple Sclerosis
por: Jakimovski, Dejan, et al.
Publicado: (2023)

Antibody response in individuals infected with SARS-CoV-2 early after the first dose of the BNT162b2 mRNA vaccine
por: Gobbi, Federico, et al.
Publicado: (2021)

A third injection of the BNT162b2 mRNA COVID-19 vaccine in kidney transplant recipients improves the humoral immune response
por: Masset, Christophe, et al.
Publicado: (2021)

Antibody maintenance and breakthrough infections 6 months after complete COVID-19 vaccination with the mRNA-1273 and BNT162b2 vaccines in hemodialysis patients
por: Rodríguez-Espinosa, Diana, et al.
Publicado: (2021)

Reduced immunogenicity of the mRNA vaccine BNT162b2 in patients with idiopathic pulmonary fibrosis
por: Karampitsakos, Theodoros, et al.
Publicado: (2022)

Beyond neutralization for BNT162b2 mRNA vaccination
por: Damani-Yokota, Payal, et al.
Publicado: (2021)

Retinal Blood Vessel Analysis Using Optical Coherence Tomography (OCT) in Multiple Sclerosis
por: Young, Nicholas, et al.
Publicado: (2023)

Antibody and T-cell response to a third dose of SARS-CoV-2 mRNA BNT162b2 vaccine in kidney transplant recipients
por: Bertrand, Dominique, et al.
Publicado: (2021)

Six month immunogenicity of COVID-19 mRNA-BNT162b2 vaccine in actively treated cancer patients: updated results of the Vax-On study
por: Nelli, F., et al.
Publicado: (2022)

Germline variants of IGHV3-53 / V3-66 are determinants of antibody responses to the BNT162b2 mRNA COVID-19 vaccine
por: Mashimo, Yoichi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qo407u3m97e1rjgfn7msr51bun